ING Group’s ChemoCentryx, Inc. CCXI Stock Holding History

ING Group’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-30,000	Closed	-$179K	–	849
2017 Q4	$179K	Hold	30,000	–	–	﹤0.01%	724
2017 Q3	$223K	Buy	+30,000	New	+$249K	﹤0.01%	770

Other funds holding CCXI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ING Group's CCXI Position: Q1 2018 in Review

ING Group sold out of ChemoCentryx, Inc. (CCXI) in Q1 2018, closing a stake of 30,000 shares — an estimated $179K sold.

ING Group first reported a position in CCXI in Q3 2017 and held it in 2 quarters. The position peaked at $223K in Q3 2017. 100 funds tracked by Wall St. Rank hold CCXI as of Q1 2018.

ING Group reported no remaining ChemoCentryx, Inc. position as of Q1 2018 after selling out during the quarter.
ING Group sold 30,000 ChemoCentryx, Inc. shares in Q1 2018, an estimated $179K.
ING Group first reported a position in ChemoCentryx, Inc. in Q3 2017 and held it in 2 quarters.
ING Group's ChemoCentryx, Inc. position peaked at $223K in Q3 2017.
100 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q1 2018.

Based on ING Group's 13F filing for Q1 2018, filed 7 May 2018.